-
Mashup Score: 3Management of Checkpoint Inhibitor-Related Toxicity - 2 year(s) ago
The goal of the conference is to bring together a multidisciplinary group of clinicians to share expertise in managing checkpoint inhibitors.
Source: www.clevelandclinicmeded.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Management of Checkpoint Inhibitor-Related Toxicity - 2 year(s) ago
The goal of the conference is to bring together a multidisciplinary group of clinicians to share expertise in managing checkpoint inhibitors.
Source: www.clevelandclinicmeded.comCategories: Hem/Oncs, Latest HeadlinesTweet-
🚨 1 mo to return of in-person/hybrid discussions of irAEs at the 4th annual Management of Checkpoint Inhibitor-Related Toxicity Feb 9-10 🚨 #irAE23 New: Networking Dinner 🍲 📚 Excited: @afreenshariffmd of @CheckpointNowMD as keynote! Register: https://t.co/ZY6MscEGnF https://t.co/WqZFnTrexb
-
-
Mashup Score: 0Management of Checkpoint Inhibitor-Related Toxicity - 3 year(s) ago
The goal of the conference is to bring together a multidisciplinary group of clinicians to share expertise in managing checkpoint inhibitors.
Source: www.clevelandclinicmeded.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Nerdy irAE holiday news: Abstract deadline has been EXTENDED to Mon Jan 9, and registration is now LIVE for Management of Checkpoint Inhibitor-Related Toxicity!! 🥳🤓 With keynote speaker endocrinologist @afreenshariffmd @dukemedicine 👏 https://t.co/ZY6MscE8y7 https://t.co/dStFvFCfvE
-
-
Mashup Score: 10Closing the Gap in Cancer Genomic Testing | NEJM - 3 year(s) ago
Perspective from The New England Journal of Medicine — Closing the Gap in Cancer Genomic Testing
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @VivekSubbiah: Closing the Gap in Cancer Genomic Testing @NEJM https://t.co/NzHvXRTAsS
-
-
Mashup Score: 1Management of Checkpoint Inhibitor-Related Toxicity - 3 year(s) ago
The goal of the conference is to bring together a multidisciplinary group of clinicians to share expertise in managing checkpoint inhibitors.
Source: www.clevelandclinicmeded.comCategories: Hem/Oncs, Latest HeadlinesTweet-
📢 #irAE23 abstracts are open!! For those miss the hybrid @ASCO @sitcancer days this is the venue for irAE-related work Save the date: 4th annual Management of Checkpoint Inhibitor-Related Toxicity 🗓 Feb 9-10 2023 Submit: https://t.co/DoKmOfONLw https://t.co/p9arsd8hpn
-
-
Mashup Score: 8
AbstractBackgroundIn the previously reported primary analyses of this phase 3 trial, 12 months of adjuvant pembrolizumab resulted in significantly longer recurrence- and distant metastasis-free sur…
Source: evidence.nejm.orgCategories: Latest Headlines, Oncologists1Tweet-
RT @jasonlukemd: KN-054 stage III #melanoma adjuvant 5 yr pembro data @NEJMEvidence https://t.co/VtIxDwkwOt Congrats Dr Eggermont et al. Re…
-
-
Mashup Score: 2Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes - Full Text View - ClinicalTrials.gov - 3 year(s) ago
Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet-
🚨 Our trial using a PARP+IO combination is still open to accrual to melanomas with any HRD mutation including any metastatic uveal melanoma with a BAP1 (or other HRD) mutation #SMR2022 🚨 https://t.co/2m5qbHaKks @ta_sussman @BrianGastmanMD https://t.co/GjHKfsfgHg
-
-
Mashup Score: 0NHCV FUND - Nirvana Healthcare Ventures - 3 year(s) ago
NHCV FUND I – Series A Healthcare Fund focused entirely on Midwest healthcare innovation and surround by World Class Healthcare centers.
Source: Nirvana Healthcare VenturesCategories: Hem/Oncs, Latest HeadlinesTweet-
Good things brewing in NE Ohio: Biotech growth in the Midwest is getting noticed - and funded 🧪🧬🔬 Science startups get a mechanism to get Series A funding locally - effort born from deep Midwest roots and an emphasis on diversity #thisisCLE https://t.co/6w7vI3di7e https://t.co/RcsW4LCbXM
-
-
Mashup Score: 0
1,539 votes and 52 comments so far on Reddit
Source: redditCategories: Hem/Oncs, Latest HeadlinesTweet-
Just when I thought I was done with the ugly crying… (Narrator: She was definitely not done with the ugly crying…) #VinScully #GOAT𓃵 #WinForVin 🎙💙⚾️ https://t.co/tgWHYkxXry
-
-
Mashup Score: 4Characteristics of Early Phase Clinical Trials for Rare Cancers: Insights From Interviews With Stakeholders - 3 year(s) ago
Background: Rare cancers occur with an incidence of no more than six cases per 100,000 people according to the definition used by the Surveillance of Rare Cancers in Europe project. For a variety of reasons (low prevalence, cytotoxicity), it is challenging to perform the necessary clinical studies to investigate the safety and efficacy of investigational medicines against such rare malignancies,…
Source: FrontiersCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @DoomsMarc: @RareDiseases @power4patients @FunchainMD @ClevelandClinic https://t.co/GvVX9EtbpM
-
Back to Back Weeks of 🧬 and 🦠 Feb 3-4 #MCIPrecisionOncology 🧬 Humbled 🙏 to speak alongside @VivekSubbiah @CharuAggarwalMD @montypal @PGrivasMDPhD Register!👇 Feb 9-10 #irAE23 🦠 Keynotes @afreenshariffmd @CheckpointNowMD & Marianne Davies @Yale Reg: https://t.co/ZY6MscE8y7 https://t.co/rwRleIkMk0